OPN-305

Opsona Therapeutics Ltd. · Phase 2 active Small molecule

At a glance

Generic name	OPN-305
Sponsor	Opsona Therapeutics Ltd.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Single and Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of NM-101 (PHASE1)
A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome (PHASE1, PHASE2)
Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome (PHASE1, PHASE2)
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

OPN-305 CI brief — competitive landscape report
OPN-305 updates RSS · CI watch RSS
Opsona Therapeutics Ltd. portfolio CI